« back to Press Releases

February 17, 2026

Recent Report That Levetiracetam Could Stop the Plaque Formation of Alzheimer’s Disease in Its Earliest Stages Is Further Confirmation of The Positive Effects of AgeneBio’s Novel Therapeutic Approach to Treating Alzheimer’s Disease

– AgeneBio retains exclusive rights to a low-dose, extended- release formulation of levetiracetam designed exclusively for treating cognitive impairment associated with various neurodegenerative indications

Baltimore, MD — February 13, 2026 — AgeneBio holds issued patents covering proprietary once-daily extended-release formulations of levetiracetam, including AGB101. The Company’s formulation provides stable drug exposure within a well characterized narrow therapeutic window for chronic use in patients with mild cognitive impairment (MCI) due to Alzheimer’s disease.

Newly published research from Northwestern University reports that levetiracetam prevented the formation of amyloid-beta plaques in preclinical models of Alzheimer’s disease. The findings further the potential disease-modifying mechanism for levetiracetam and reinforce growing scientific interest in targeting early neuronal hyperactivity. AgeneBio has published an 18-month phase 2b human clinical trial (Mohs, et al, 2024, Bakker et al. 2024) reporting that AGB101, showed a trend to a reduction of cognitive decline in a subset of patients with MCI due to Alzheimer’s disease and a statistically significant reduction in neuronal atrophy in these patients.

“These Northwestern findings extend the biological rationale and observed biological data behind our program,” said Dr. Michela Gallagher, Founder & Chief Executive Officer of AgeneBio. “We designed AGB101 to address neuronal hyperactivity early in the disease process. These independent data suggesting levetiracetam may also influence amyloid biology from this study and others further strengthen the scientific foundation of AgeneBio’s novel therapeutic approach to treating cognitive impairment in CNS disorders in their earliest stages.”

AgeneBio believes that AGB-101’s differentiated pharmacokinetic profile of its formulation — enabled by its patent-protected, once-daily formulation — positions the Company uniquely within the levetiracetam space for the early treatment of neurodegenerative disorders.

The Company retains exclusive rights to this formulation and approach.

AgeneBio continues to evaluate strategic and development pathways for AGB101, including potential partnerships, regulatory engagement, and further clinical investigation.

AGB101 remains investigational and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority for the treatment of Alzheimer’s disease.

About AgeneBio

AgeneBio is a clinical-stage biopharmaceutical company focused on developing therapies that address early drivers of neurodegenerative disease. The Company’s lead program, AGB101, is a patented once-daily extended-release formulation of levetiracetam designed for patients with mild cognitive impairment due to Alzheimer’s disease.

 

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding the potential therapeutic benefits of AGB101, future development plans, regulatory strategy, intellectual property protection, and business strategy. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. AgeneBio undertakes no obligation to update these statements except as required by law.

###

Media Contact:

Hilary Lefebvre

hilary@foxcroftstrategy.com

(212) 300-4929